2022-03-31 08:00
Infant Bacterial Therapeutics publishes Annual Report for 2021
Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s...
2022-02-04 20:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities...
2022-01-19 23:30
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after...
2022-01-10 22:30
Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid...
2021-12-27 22:30
Infant Bacterial Therapeutics today announces new patent protection approvals in Brazil and in Hong Kong
Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering...
2021-12-10 08:00
Infant Bacterial Therapeutics CFO leaves the company
Infant Bacterial Therapeutics ABs CFO Marie Louise Alamaa left the company to pursue new opportunities. IBT’s Controller, Michael Owens, has assumed...
2021-12-06 19:47
A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
A blinded evaluation of IBT’s Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology®...
2021-10-29 16:15
Nomination Committee appointed for the 2022 Annual General Meeting (AGM) in Infant Bacterial Therapeutics (IBT).
Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the AGM, which is planned to be held on May 4, 2022. The Nomination...
2021-10-29 08:00
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase...
2021-09-30 19:00
Next recruitment milestone reached in IBT’s Phase III Study.
Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing...